- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
670
Companies which are more than 50% undervalued based on analyst price target.
670 companies
Werewolf Therapeutics
Market Cap: US$61.7m
A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.
HOWL
US$1.35
7D
3.1%
1Y
-33.2%
Cue Biopharma
Market Cap: US$60.3m
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
CUE
US$0.78
7D
-0.03%
1Y
32.2%
Clene
Market Cap: US$59.4m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$6.03
7D
13.3%
1Y
1.7%
Adicet Bio
Market Cap: US$59.4m
A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
ACET
US$0.72
7D
0.04%
1Y
-51.3%
Earth Science Tech
Market Cap: US$59.3m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.20
7D
0%
1Y
24.9%
Precision BioSciences
Market Cap: US$59.3m
A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
DTIL
US$5.07
7D
3.5%
1Y
-49.0%
Karyopharm Therapeutics
Market Cap: US$58.4m
A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
KPTI
US$6.60
7D
-7.2%
1Y
-39.7%
TRUBAR
Market Cap: CA$80.8m
Operates as a consumer products company with diversified assets in the plant-based and wellness consumer product categories in Canada.
TRBR
CA$0.76
7D
11.8%
1Y
24.6%
FluoGuide
Market Cap: SEK 543.4m
A clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
FLUO
SEK 39.90
7D
-1.7%
1Y
0.3%
ALX Oncology Holdings
Market Cap: US$57.8m
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
ALXO
US$1.22
7D
4.3%
1Y
-36.1%
PDS Biotechnology
Market Cap: US$57.4m
A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.
PDSB
US$1.20
7D
-3.2%
1Y
-59.0%
Vitrafy Life Sciences
Market Cap: AU$86.2m
Engages in the research, development, and commercialization of cryopreservation solutions in Australia.
VFY
AU$1.35
7D
0%
1Y
n/a
Noile-Immune Biotech
Market Cap: JP¥8.4b
Researches and develops CAR-T cells for cancer immunotherapies.
4893
JP¥193.00
7D
6.0%
1Y
3.2%
Inotiv
Market Cap: US$55.0m
Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally.
NOTV
US$1.64
7D
-3.0%
1Y
22.4%
Barinthus Biotherapeutics
Market Cap: US$54.2m
A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.
BRNS
US$1.24
7D
10.7%
1Y
-3.1%
Decibel Cannabis
Market Cap: CA$75.0m
An integrated cannabis company, engages in the cannabis cultivation in Canada.
DB
CA$0.13
7D
-3.8%
1Y
92.3%
Serina Therapeutics
Market Cap: US$54.1m
A biotechnology company, develops drugs to treat neurological diseases and pain.
SER
US$5.09
7D
-4.3%
1Y
-36.2%
Cantourage Group
Market Cap: €46.1m
Operates as a medical cannabis company in Europe.
HIGH
€3.70
7D
-5.9%
1Y
-28.2%
Captor Therapeutics Spolka Akcyjna
Market Cap: zł194.6m
A biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.
CTX
zł35.20
7D
-14.4%
1Y
-57.0%
Ascelia Pharma
Market Cap: SEK 501.8m
A biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.
ACE
SEK 4.33
7D
-12.4%
1Y
86.8%
PolyPid
Market Cap: US$53.2m
A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
PYPD
US$3.45
7D
3.0%
1Y
0.3%
Actinium Pharmaceuticals
Market Cap: US$52.7m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$1.58
7D
-11.2%
1Y
-11.2%
Lytix Biopharma
Market Cap: NOK 528.3m
A clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.
LYTIX
NOK 7.74
7D
-3.0%
1Y
-12.4%
Amplia Therapeutics
Market Cap: AU$79.5m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.15
7D
-6.1%
1Y
63.2%
BioXcel Therapeutics
Market Cap: US$52.0m
Together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
BTAI
US$3.79
7D
-6.4%
1Y
-56.6%
SkinBioTherapeutics
Market Cap: UK£38.2m
A life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.
SBTX
UK£0.15
7D
3.5%
1Y
24.2%
INmune Bio
Market Cap: US$51.0m
A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
INMB
US$1.95
7D
-3.9%
1Y
-66.8%
Imugene
Market Cap: AU$77.9m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.27
7D
-5.3%
1Y
-85.3%
Vivoryon Therapeutics
Market Cap: €43.1m
Operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines.
VVY
€1.64
7D
-3.1%
1Y
-15.2%
Nykode Therapeutics
Market Cap: NOK 503.5m
A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases.
NYKD
NOK 1.54
7D
0.1%
1Y
-70.2%
MAIA Biotechnology
Market Cap: US$49.2m
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
MAIA
US$1.54
7D
0%
1Y
-51.4%
Vext Science
Market Cap: CA$68.1m
Through its subsidiaries, provides integrated agricultural technology, services, and property management services in the cannabis industry in the United States.
VEXT
CA$0.30
7D
10.9%
1Y
32.6%
Guard Therapeutics International
Market Cap: SEK 459.8m
A pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.
GUARD
SEK 22.80
7D
2.2%
1Y
-20.8%
TMS
Market Cap: JP¥7.2b
Engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities.
4891
JP¥161.00
7D
1.3%
1Y
-20.3%
Verrica Pharmaceuticals
Market Cap: US$48.7m
A dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States.
VRCA
US$5.11
7D
-8.8%
1Y
-73.3%
Veru
Market Cap: US$48.3m
A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
VERU
US$3.37
7D
3.7%
1Y
-60.3%